Core Viewpoint - Eupraxia Pharmaceuticals Inc. has filed a preliminary prospectus supplement for a proposed public offering of common shares to advance its clinical-stage biotechnology initiatives, particularly focusing on its proprietary Diffusphere™ technology for drug delivery [1][4]. Group 1: Offering Details - The company plans to offer common shares and may grant underwriters a 30-day option to purchase an additional 15% of the shares offered [2]. - The final terms of the offering will be determined at the time of pricing, and the completion of the offering is subject to customary closing conditions, including necessary approvals from the Toronto Stock Exchange and Nasdaq [2]. - Cantor and LifeSci Capital are acting as joint book-running managers, with Bloom Burton as a co-manager for the offering [3]. Group 2: Use of Proceeds - The net proceeds from the offering will primarily support the advancement of EP-104GI for Eosinophilic Esophagitis, including ongoing preclinical studies and Phase 2 clinical trials, as well as preparations for a Phase 3 trial [4]. - Additional funds will be allocated to expand clinical studies for EP-104GI in other gastrointestinal indications and to support research and development of new pipeline candidates [4]. - The company also plans to use a portion of the proceeds for general corporate purposes, including employee salaries, working capital, and expanding its intellectual property portfolio [4]. Group 3: Company Overview - Eupraxia Pharmaceuticals is focused on developing locally delivered, extended-release products aimed at addressing significant unmet medical needs [7]. - The company's proprietary Diffusphere™ technology is designed to facilitate targeted drug delivery of both existing and novel drugs [7].
Eupraxia Pharmaceuticals Announces Proposed Public Offering